Abstract
One thing we know for certain after decades of functional imaging in schizophrenia is that it is not a disorder that can simply be attributed to circumscribed lesions in the brain. It is, in other words, a disorder of the connectivity of the brain. In this overview, we will consider the power of connectivity analyses of functional MRI (and PET) data as tools for translational neuroscience. We describe the patterns of functional and effective disconnectivity seen in schizophrenia and particular psychotic symptoms, those that appear to be attributable to genetic and/or environmental risk factors for psychosis, the potential of these disconnectivities as trait and state biomarkers, and their sensitivity to drug effects. We conclude that substantial work needs to be done on standardising connectivity analyses across laboratories and that disconnectivity studies should be an integral part of drug discovery programmes.
Keywords: Connectivity, fMRI, schizophrenia
Current Pharmaceutical Design
Title: Connecting the Brain and New Drug Targets for Schizophrenia
Volume: 15 Issue: 22
Author(s): H. C. Whalley, J. D. Steele, P. Mukherjee, L. Romaniuk, A. M. McIntosh, J. Hall and S. M. Lawrie
Affiliation:
Keywords: Connectivity, fMRI, schizophrenia
Abstract: One thing we know for certain after decades of functional imaging in schizophrenia is that it is not a disorder that can simply be attributed to circumscribed lesions in the brain. It is, in other words, a disorder of the connectivity of the brain. In this overview, we will consider the power of connectivity analyses of functional MRI (and PET) data as tools for translational neuroscience. We describe the patterns of functional and effective disconnectivity seen in schizophrenia and particular psychotic symptoms, those that appear to be attributable to genetic and/or environmental risk factors for psychosis, the potential of these disconnectivities as trait and state biomarkers, and their sensitivity to drug effects. We conclude that substantial work needs to be done on standardising connectivity analyses across laboratories and that disconnectivity studies should be an integral part of drug discovery programmes.
Export Options
About this article
Cite this article as:
Whalley C. H., Steele D. J., Mukherjee P., Romaniuk L., McIntosh M. A., Hall J. and Lawrie M. S., Connecting the Brain and New Drug Targets for Schizophrenia, Current Pharmaceutical Design 2009; 15 (22) . https://dx.doi.org/10.2174/138161209788957500
DOI https://dx.doi.org/10.2174/138161209788957500 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Evolution of Extensively Drug Resistant Tuberculosis (XDR-TB): History, Status and Issues for Global Control
Infectious Disorders - Drug Targets Biosimilars: Current Scientific and Regulatory Considerations
Current Clinical Pharmacology Microbial Metabolomics
Current Genomics What Animal Models are Best to Test Novel Rheumatoid Arthritis Therapies?
Current Rheumatology Reviews Chondroitin Sulfate and Sulfur Containing Chondroprotective Agents: Is there a Basis for their Pharmacological Action?
Current Rheumatology Reviews Targeting Angiogenesis in Renal Cell Carcinoma
Current Cancer Drug Targets Cytokines and their Antagonists as Therapeutic Agents
Current Medicinal Chemistry Pharmacological Countermeasures for the Acute Radiation Syndrome
Current Molecular Pharmacology Lessons from Nature: Sources and Strategies for Developing AMPK Activators for Cancer Chemotherapeutics
Anti-Cancer Agents in Medicinal Chemistry Pharmacological Evaluation of Jambrushila Tablet on Animal Model of Type-2 Diabetes
The Natural Products Journal Management of Ovarian Cancer In Younger Women
Reviews on Recent Clinical Trials The Roles of MicroRNAs in Atherosclerosis
Current Medicinal Chemistry Acute Severe Colitis: Infliximab and/or Cyclosporine?
Current Drug Targets Multiple-Target Drugs: Inhibitors of Heat Shock Protein 90 and of Histone Deacetylase
Current Drug Targets Edging Toward Personalized Medicine
Current Pharmacogenomics Modified LDL Immune Complexes and Cardiovascular Disease
Current Medicinal Chemistry Trends in Metabolic Syndrome and Gene Networks in Human and Rodent Models
Endocrine, Metabolic & Immune Disorders - Drug Targets Impaired Insulin Sensitivity and Secretion in Patients with Alzheimer’s Disease: The Relationship with Other Atherosclerosis Risk Factors
Current Vascular Pharmacology SIRT1 Deacetylase Activity and the Maintenance of Protein Homeostasis in Response to Stress: An Overview
Protein & Peptide Letters Innate Immune Inflammatory Response in the Acutely Ischemic Myocardium
Medicinal Chemistry